WC
ABBV icon

Whitnell & Co’s AbbVie ABBV Stock Holding History

Whitnell & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$3.94M Sell
44,468
-4,401
-9% -$365K 1.21% 25
2019
Q3 		$3.7M Buy
48,869
+2,180
+5% +$149K 1.24% 26
2019
Q2 		$3.4M Buy
46,689
+179
+0.4% +$14.1K 1.27% 27
2019
Q1 		$3.75M Sell
46,510
-2,407
-5% -$197K 1.44% 22
2018
Q4 		$4.51M Sell
48,917
-816
-2% -$71.8K 2% 11
2018
Q3 		$4.7M Buy
49,733
+1,211
+2% +$115K 1.86% 12
2018
Q2 		$4.5M Sell
48,522
-2,970
-6% -$290K 1.87% 11
2018
Q1 		$4.87M Buy
51,492
+2,973
+6% +$327K 2.04% 9
2017
Q4 		$4.69M Sell
48,519
-2,411
-5% -$227K 1.97% 11
2017
Q3 		$4.53M Sell
50,930
-125
-0.2% -$9.52K 1.97% 9
2017
Q2 		$3.7M Buy
51,055
+2,908
+6% +$195K 1.64% 16
2017
Q1 		$3.14M Buy
48,147
+1,280
+3% +$80.5K 1.41% 23
2016
Q4 		$2.94M Sell
46,867
-2,158
-4% -$132K 1.36% 21
2016
Q3 		$3.09M Sell
49,025
-1,540
-3% -$99.7K 1.06% 25
2016
Q2 		$3.13M Buy
50,565
+1,000
+2% +$60.9K 1.02% 22
2016
Q1 		$2.83M Buy
49,565
+4,300
+9% +$240K 1.05% 29
2015
Q4 		$2.68M Sell
45,265
-1,270
-3% -$73.1K 1.01% 27
2015
Q3 		$2.53M Buy
46,535
+7,398
+19% +$482K 1% 28
2015
Q2 		$2.63M Buy
39,137
+2,700
+7% +$176K 0.95% 31
2015
Q1 		$2.13M Sell
36,437
-2,100
-5% -$127K 0.8% 36
2014
Q4 		$2.52M Buy
38,537
+350
+0.9% +$22.1K 0.95% 29
2014
Q3 		$2.21M Buy
38,187
+400
+1% +$22.2K 0.88% 28
2014
Q2 		$2.13M Sell
37,787
-825
-2% -$43.3K 0.97% 29
2014
Q1 		$1.99M Sell
38,612
-1,950
-5% -$98.6K 0.93% 32
2013
Q4 		$2.14M Sell
40,562
-450
-1% -$22.1K 0.98% 33
2013
Q3 		$1.83M Sell
41,012
-1,760
-4% -$78K 0.9% 33
2013
Q2 		$1.77M Buy
+42,772
New +$1.87M 0.88% 33

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Whitnell & Co's ABBV Position: Q4 2019 in Review

Whitnell & Co reduced its AbbVie (ABBV) stake by 9% in Q4 2019, selling an estimated $365K and leaving 44,468 shares worth $3.94M. The position accounts for 1.21% of the portfolio, ranked #25.

Whitnell & Co first reported a position in ABBV in Q2 2013 and has held it in 27 quarters since. The position peaked at $4.87M in Q1 2018. 2,243 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

  • Whitnell & Co held 44,468 shares of AbbVie worth $3.94M as of Q4 2019.
  • Whitnell & Co sold 4,401 AbbVie shares in Q4 2019, an estimated $365K.
  • AbbVie made up 1.21% of Whitnell & Co's portfolio in Q4 2019, its #25 holding.
  • Whitnell & Co first reported a position in AbbVie in Q2 2013 and has held it in 27 quarters since.
  • Whitnell & Co's AbbVie position peaked at $4.87M in Q1 2018.
  • 2,243 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on Whitnell & Co's 13F filing for Q4 2019, filed 11 Feb 2020.